Clinical Trial Update: Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ONC201 in relapsed/refractory non-Hodgkin's lymphoma, including phase 1 and phase 2 cohorts; study status terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Gastric Mantle Cell Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-04